Brief Title
Intravitreal Bevacizumab for the Treatment of Central Serous Chorioretinopathy
Brief Summary
Central serous chorioretinopathy (CSC) has been known since it was first described by Von
Graefe and termed "idiopathic detachment of the macula" in 1866, is a well-characterized
disorder leading to serous neurosensory elevation of the central macula. The acute form of
the disease is associated with focal leakage at the level of the retinal pigment epithelium
(RPE) demonstrated with fluorescein angiography (FA). The disorder is self-limited in the
majority of patients, who also regain excellent vision. Occasionally, the neurosensory
detachment persists and leads to pigment epithelial and photoreceptor damage with visual
impairment.
The purpose of this clinical study is report the use of intravitreal bevacizumab is a new
option in the treatment of the chronic or recurrent CSC.
Study Phase
Phase 2/Phase 3
Study Type
Interventional
Condition
Central Serous Chorioretinopathy
Intervention
Intravitreal injection of Bevacizumab
Publications
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
Recruitment Information
Recruitment Status
Drug
Start Date
April 2006
Completion Date
August 2006
Eligibility Criteria
Inclusion Criteria
- Any visual acuity.
- Central serous chorioretinopathy
Gender
All
Ages
20 Years - 50 Years
Contacts
Mitzy E Torres Soriano, MD, 525510841400, [email protected]
Location Countries
Mexico
Location Countries
Mexico
Administrative Informations
NCT ID
NCT00418431
Organization ID
APEC-0016
Study Sponsor
Asociación para Evitar la Ceguera en México
Study Sponsor
Mitzy E Torres Soriano, MD, Principal Investigator, Asociación para Evitar la Ceguera en México
Verification Date
June 2006